Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

NEWS

Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra
Annovis Bio Inc. (NYSE: ANVS) has filed three new patents for innovative combination therapies involving its lead compound, buntanetap. These patents cover combinations of buntanetap with Trulicity (dulaglutide), Viagra (sildenafil), or a combination of all three, aimed at treating neurodegenerative diseases like Alzheimer's and Parkinson's.
Recent preclinical studies have shown that combining buntanetap with a GLP-1 agonist (like Trulicity) or PDE5 inhibitors (like Viagra) improves cognitive function in Alzheimer's mouse models beyond levels observed in healthy controls. The company's CEO, Maria Maccecchini, Ph.D., stated that early data suggests a strong synergistic effect, potentially restoring and improving cognition beyond normal levels.
As buntanetap has completed Phase 3 studies as a standalone treatment, and both Trulicity and Viagra are FDA-approved, these combinations are well-positioned for Phase 3 human trials. This development expands Annovis's pipeline and advances its mission to enhance cognition for those suffering from neurodegenerative disorders.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
10K Views
Comment
Sign in to post a comment
    Spread kindness and love. Life is short. Don’t let greed eat you.
    2311Followers
    105Following
    24KVisitors
    Follow